| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Total income | 0.0 | 0.0 | 0.0 |
| Profit before exceptional items & tax | -0.4 | -0.2 | -0.2 |
| Profit before tax | -0.4 | -0.2 | -0.2 |
| Net profit | -0.4 | -0.2 | -0.3 |
| Operating margin | 0.0% | 0.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, BSE: 531686. Figures extracted from the filing.
Advik Laboratories Ltd: key numbers
- Share price
- ₹2.08
- Market cap
- ₹3.98 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-1.02 Cr
- P/E (TTM)
- -3.8×Sector 50.4×
- Promoter holding
- 35.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advik Laboratories Ltd
All →Advik Laboratories Other Announcement
MPS Pharmaa Limited announced the availability of its FY 2025-26 Annual Report on its website. It also requested shareholders to update their KYC and PAN details.
Advik Laboratories Annual General Meeting
The company submitted its 32nd Annual Report and AGM notice for FY 2025-26. The meeting is scheduled for September 29, 2026.
Advik Laboratories Board Meeting Outcome
MPS Pharmaa Ltd announced the outcome of its board meeting, fixing the 32nd AGM date and recommending new director and auditor appointments for shareholder approval.
Advik Laboratories Q1 FY27 Results: Net Loss of ₹0.2 Cr, Loss Widens
Advik Laboratories Ltd reported a net loss of ₹0.2 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.2 Cr